Portal de Periódicos da CAPES

Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial

2009; Lippincott Williams & Wilkins; Volume: 181; Issue: 3 Linguagem: Inglês

10.1016/j.juro.2008.11.032

1527-3792

Ian M. Thompson, Catherine M. Tangen, Jorge C. Paradelo, M. Scott Lucia, Gary J. Miller, Dean A. Troyer, Edward M. Messing, Jeffrey D. Forman, Joseph L. Chin, Gregory P. Swanson, Edith Canby‐Hagino, E. David Crawford,

Hepatocellular Carcinoma Treatment and Prognosis

Extraprostatic disease will be manifest in a third of men after radical prostatectomy. We present the long-term followup of a randomized clinical trial of radiotherapy to reduce the risk of subsequent metastatic disease and death.A total of 431 men with pT3N0M0 prostate cancer were randomized to 60 to 64 Gy adjuvant radiotherapy or observation. The primary study end point was metastasis-free survival.Of 425 eligible men 211 were randomized to observation and 214 to adjuvant radiation. Of those men under observation 70 ultimately received radiotherapy. Metastasis-free survival was significantly greater with radiotherapy (93 of 214 events on the radiotherapy arm vs 114 of 211 events on observation; HR 0.71; 95% CI 0.54, 0.94; p = 0.016). Survival improved significantly with adjuvant radiation (88 deaths of 214 on the radiotherapy arm vs 110 deaths of 211 on observation; HR 0.72; 95% CI 0.55, 0.96; p = 0.023).Adjuvant radiotherapy after radical prostatectomy for a man with pT3N0M0 prostate cancer significantly reduces the risk of metastasis and increases survival.